What is transfection
Transfection is a foundational technique in molecular and cellular biology that involves the introduction of nucleic acids—such as DNA, RNA, or oligonucleotides—into eukaryotic cells. This process allows researchers to study gene function, protein expression, and cellular responses by manipulating genetic material within cells. Depending on the application, transfection can be transient, allowing temporary expression of genes, or stable, resulting in the long-term integration of genetic material into the host genome. The method is widely employed in fields such as gene therapy, drug discovery, and cancer research.
A range of transfection techniques have been developed to accommodate various cell types and experimental objectives. Commonly used methods include lipid-mediated transfection, electroporation, calcium phosphate precipitation, and polymer-based systems. Lipid-based reagents form complexes with nucleic acids and facilitate their uptake through endocytosis, making them suitable for many adherent cell lines. Electroporation, which uses electrical pulses to transiently permeabilize the cell membrane, is especially effective for hard-to-transfect suspension cells. The choice of method depends on factors such as cell type, transfection efficiency, toxicity, and whether the desired outcome is transient or stable gene expression.
Transfection plays a critical role in biomedical research, enabling the functional analysis of genes, the development of recombinant proteins, and the creation of genetically modified cell models. In therapeutic contexts, transfection technologies are essential for delivering gene-editing tools such as CRISPR/Cas9 or siRNA-based gene silencing agents. Recent advances in transfection reagents—including biodegradable nanoparticles and targeted delivery systems—have improved efficiency while minimizing cytotoxicity, paving the way for clinical applications. As the demand for precise genetic manipulation grows, transfection continues to be a vital tool in advancing both basic and translational life science research.
What is liver transfection
Liver transfection refers to the delivery of genetic material specifically into liver cells, either in vitro using hepatocyte cell lines or in vivo through targeted delivery to hepatic tissue. This approach is central to studying liver-specific gene regulation, modeling hepatic diseases, and developing therapies for conditions such as viral hepatitis, metabolic disorders, and hepatocellular carcinoma. The liver’s high vascularization and fenestrated endothelium make it an accessible target for nucleic acid delivery, facilitating efficient uptake of genetic constructs under optimized conditions.
Techniques for liver transfection vary depending on the experimental system and desired outcome. In vitro transfection commonly utilizes lipid-based or polymer-based reagents to introduce plasmids, siRNA, or mRNA into liver-derived cell lines such as HepG2, Huh7, or SNU-398. For in vivo applications, strategies include hydrodynamic tail vein injection, lipid nanoparticles, viral vectors, or biodegradable polymer carriers to achieve liver-targeted gene delivery. The efficiency of liver transfection is influenced by multiple factors, including the choice of transfection reagent, the physicochemical properties of the nucleic acid cargo, and the biological characteristics of the liver tissue or cell model.
Liver transfection has significant implications in gene therapy and functional genomics, enabling the modulation of liver-specific pathways and the evaluation of therapeutic gene candidates. It is also instrumental in preclinical drug screening, where transfected hepatic cells serve as models for assessing toxicity, metabolism, and drug response. Advances in liver-targeted delivery systems have improved tissue specificity and reduced off-target effects, contributing to safer and more effective gene modulation strategies. As research into liver diseases expands, liver transfection remains an essential tool for dissecting molecular mechanisms and translating findings into clinical interventions.
1 H22 Allograft Model
The H22 cell line is a murine hepatocellular carcinoma (HCC) line originally derived from a liver tumor in a male Kunming mouse. It is widely used in syngeneic mouse models, particularly in immunocompetent BALB/c mice, to evaluate immunotherapies and liver cancer drug efficacy in a native immune microenvironment.
Learn more about H22 Allograft Model
2 Hepa 1-6 Allograft Syngeneic Model
Hepa 1-6 is a mouse hepatoma cell line established from a BW7756 liver tumor induced in a C57L mouse. It is commonly implanted in immunocompetent C57BL/6 mice as a syngeneic model to study liver cancer progression, immune responses, and checkpoint inhibitor therapies.
Learn More about Hepa 1-6 Allograft Syngeneic Model
3 Hep3B Xenograft Model
The Hep3B cell line was established from a liver biopsy of an 8-year-old Black male with hepatocellular carcinoma and is characterized by its lack of p53 expression and hepatitis B virus (HBV) integration. It is frequently used in xenograft models in immunodeficient mice (e.g., nude or NOD-SCID) to investigate HBV-associated HCC.
Learn More about Hep3B Xenograft Model
4 Hep G2 Xenograft Model
Derived from the liver tumor of a 15-year-old Caucasian male with hepatoblastoma, the Hep G2 cell line retains many features of differentiated hepatocytes. It is used in xenograft models to study hepatic metabolism, drug-induced hepatotoxicity, and hepatocellular carcinoma in immunodeficient hosts.
Learn more about Hep G2 Xenograft Model
5 HUH-7 Xenograft Model
The Huh7 xenograft model is derived from the Huh7 human hepatocellular carcinoma cell line, which was established in 1982 from a liver tumor resected from a 57-year-old Japanese male. This well-differentiated hepatocyte-derived cell line is frequently used in xenograft studies to investigate liver cancer progression, drug metabolism, and antiviral therapies.
Learn More about HUH-7 Xenograft Model
6 SK-HEP-1 Xenograft Model
The SK-HEP-1 xenograft model originates from the SK-HEP-1 cell line, which was established in 1971 from the ascitic fluid of a patient with hepatic metastases of adenocarcinoma. Although initially classified as hepatic carcinoma, SK-HEP-1 cells exhibit endothelial-like properties and are commonly used in tumor angiogenesis studies and preclinical evaluations of liver-targeted therapeutics.
Learn More about SK-HEP-1 Xenograft Model
7 SNU-398 Xenograft Model
SNU-398 is a human hepatocellular carcinoma cell line derived from a 54-year-old Korean male patient. Originally established by the Korea Cell Line Bank, it is characterized by TP53 mutations and is used in xenograft studies for targeted therapy evaluation and molecular pathway analysis in HCC.
Learn more about SNU-398 Xenograft Model
8 SMMC-7721 Xenograft Model
SMMC-7721 is a human hepatoma cell line derived from the liver tissue of a Chinese male with primary liver cancer. It was established at the Shanghai Second Military Medical University and is commonly used in xenograft models to evaluate chemotherapeutic and molecular-targeted agents in liver cancer.